Article ID Journal Published Year Pages File Type
319282 European Neuropsychopharmacology 2006 10 Pages PDF
Abstract

The efficacy and safety of fluoxetine (20–80 mg) was compared with placebo in 144 veterans [36.2 years], diagnosed with combat-related post-traumatic stress disorder (PTSD) selected from a 12-week acute and 24-week relapse prevention PTSD trial. In the acute phase, improvements were greater with fluoxetine than placebo in the disease-specific outcome measures: Treatment Outcome PTSD (TOP-8) total scores (SE):− 9.05 (0.90) and − 5.20 (1.23), p = 0.001; Clinician Administered PTSD Scale (CAPS) total scores:−31.12 (2.72) and − 16.07 (4.24), p < 0.001; all CAPS subscores; Davidson Trauma Scale (DTS) total scores; and other general outcome measures. In the maintenance phase, fluoxetine was superior to placebo in sustaining improvement in TOP-8 [− 1.01 (0.91) and 1.56 (0.95)] and CAPS [− 4.93 (3.54) and 5.48 (3.66)]. The risk of relapse in the placebo arm was significantly greater than in the fluoxetine arm (log-rank test χ2 = 4.090, df = 1, p = 0.048). Fluoxetine was well tolerated at a mean daily dose of 65 mg.

Related Topics
Life Sciences Neuroscience Biological Psychiatry
Authors
, ,